[144] ARDELYX, INC. SEC Filing
An ARDELYX, INC. (ARDX) affiliate filed a Form 144 Notice of Proposed Sale of Securities, indicating an intent to sell common stock derived from the vesting of 10,388 restricted stock units on February 19, 2026. The filing also notes a previous sale of 11,086 shares on November 21, 2025, for $61,382.07. This filing is a disclosure of proposed resale and not a company operational development.
Ardelyx stock falls after Q1 print on outlook (ARDX:NASDAQ)
Ardelyx (ARDX) experienced a stock decline despite reporting better-than-expected Q4 2025 revenue. The fall is attributed to Jefferies' concerns over a softer-than-expected outlook for the company's bowel disease therapy, Ibsrela, in the current quarter, as highlighted by CFO Sue Hohenleitner during the earnings call.
Ardelyx (NASDAQ:ARDX) Trading Down 10.4% on Disappointing Earnings
Ardelyx (NASDAQ: ARDX) shares fell 10.4% after reporting Q4 EPS of -$0.01, missing the consensus of $0.02, despite revenue beating estimates at $125.2 million. The decline highlights concerns about near-term profitability, even as analysts largely maintain a "Buy" rating with a consensus price target of $15.09, citing strong commercial momentum for IBSRELA. Insider selling by Laura A. Williams and varying institutional investor activities were also noted in the report.
H.C. Wainwright raises Ardelyx stock price target on patent win
H.C. Wainwright increased its price target for Ardelyx (NASDAQ:ARDX) to $18 from $10, maintaining a Buy rating, following a new patent win for tenapanor that extends its exclusivity to 2042. The company also reported strong Q4 and FY25 Ibsrela revenues and initiated a Phase 3 trial for IBSRELA in chronic idiopathic constipation, attracting similar positive sentiment from Raymond James and BTIG.
Ardelyx, Inc. (NASDAQ:ARDX) Q4 2025 Earnings Call Transcript
Ardelyx, Inc. held its Q4 2025 earnings call, highlighting an "extraordinary year" driven by strong performance from IBSRELA and strategic execution for XPHOZAH. The company announced plans to expand IBSRELA's label to include chronic idiopathic constipation (CIC) and initiated development for a next-generation NHE3 inhibitor. Ardelyx reported significant revenue growth for IBSRELA and maintained a strong financial position, projecting continued growth and progression towards profitability.
Ardelyx Lead Drug Growth Fails To Lift Sentiment, Stock Drops
Ardelyx Inc. (NASDAQ: ARDX) shares dropped in premarket trading despite reporting strong Q4 2025 financial results, with sales beating consensus and lead drugs IBSRELA and XPHOZAH showing significant growth. The company expects continued revenue growth for both drugs in 2026 and beyond, with a projected $1 billion annual revenue for IBSRELA by 2029. Ardelyx is also advancing its pipeline with a Phase 3 trial for IBSRELA's CIC indication and a new NHE3 inhibitor, RDX10531, which suggests that the stock's decline is due to company-specific factors rather than broader market trends.
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?
Ardelyx (ARDX) shares dropped in pre-market trading after missing Q4 earnings expectations. Despite this, H.C. Wainwright analysts significantly raised their price target for ARDX from $10 to $18 and maintained a 'Buy' rating, citing encouragement from a new patent for oral formulations of Tenapor (Ibsrela and Xpozah) which expires in 2042. The patent extends protection for their key medicines, which have now been listed in the FDA's Orange Book.
ARDX: IBSRELA revenue soared 73% in 2025, with 2026 guidance targeting at least 50% further growth
Ardelyx (ARDX) reported a 22% revenue growth in 2025, primarily driven by a 73% surge in IBSRELA revenue, alongside resilience from XPHOZAH. The company's 2026 guidance projects at least 50% growth for IBSRELA and continued pipeline expansion, supported by a strong cash position. This information is based on Ardelyx's Q4 2025 Audio Transcript from February 19, 2026.
Ardelyx (NASDAQ:ARDX) Releases Earnings Results
Ardelyx (NASDAQ:ARDX) reported its quarterly earnings, missing EPS estimates at ($0.01) against a $0.02 consensus, yet exceeding revenue expectations with $125.22 million. The stock saw a slight increase of 0.3% to $6.74, driven by trading volume above its average. Despite insider sales, institutional investors increased their stakes, and Wall Street analysts currently hold a "Buy" consensus rating with an average target price of $14.36.
Ardelyx: Q4 Earnings Snapshot
Ardelyx Inc. (ARDX) reported a fourth-quarter loss of $407,000, or less than 1 cent per share, significantly missing analyst expectations of 2 cents per share. Despite the loss, the biotechnology company exceeded revenue forecasts with $125.2 million for the quarter. For the full year, Ardelyx's loss widened to $61.6 million on revenues of $407.3 million, while its shares have risen 16% year-to-date and over 6% in the last 12 months.
Ardelyx: Q4 Earnings Snapshot
Ardelyx Inc. (ARDX) reported a Q4 loss of $407,000, or less than 1 cent per share, despite analyst expectations for a profit. The biotechnology company exceeded revenue forecasts with $125.2 million. For the full year, Ardelyx's loss widened to $61.6 million, and its shares have increased 16% since the beginning of the year.
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Ardelyx, Inc. (Nasdaq: ARDX) announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant revenue growth for its key products, IBSRELA and XPHOZAH. IBSRELA revenue grew 73% in 2025 to $274.2 million, with projections to reach $1 billion annually by 2029. The company also advanced its clinical development programs, including a Phase 3 trial for IBSRELA for chronic idiopathic constipation and the launch of a new NHE3 inhibitor program.
Insights Into Ardelyx (ARDX) Q4: Wall Street Projections for Key Metrics
Wall Street analysts project Ardelyx (ARDX) to report Q4 earnings of $0.02 per share, consistent with the prior year, on revenues of $117.57 million, a 1.2% year-over-year increase. The consensus EPS estimate was recently cut by 50%. Analysts also forecast "Revenues- Product sales, net" at $114.14 million (+2.8%), with IBSRELA sales at $85.75 million (+59.3%) and XPHOZAH sales at $28.39 million (-50.3%).
Short Interest in Ardelyx, Inc. (NASDAQ:ARDX) Declines By 15.0%
Short interest in Ardelyx, Inc. (NASDAQ:ARDX) decreased by 15.0% in January, totaling 18,557,299 shares and representing 8.0% of the company's shares. Insiders have recently sold 114,868 shares, while institutional investors have adjusted their positions. Analysts maintain a consensus "Buy" rating with an average target price of $14.36, and several firms have recently raised their price targets for the stock.
Ardelyx, Inc. (ARDX) Stock Analysis: Healthcare Innovator With Over 100% Potential Upside
Ardelyx, Inc. (ARDX) is highlighted as a compelling investment due to its innovative pipeline, including IBSRELA and XPHOZAH, and strong analyst confidence projecting over 100% potential upside. Despite current financial challenges like negative EPS and free cash flow, the biotechnology firm's revenue growth and stock performance above moving averages suggest future profitability. The analysis emphasizes that Ardelyx is well-positioned for long-term growth, making it attractive for investors with a high-risk tolerance.
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ardelyx (ARDX) is projected to report flat earnings but higher revenues for the quarter ended December 2025, with expectations for $0.02 EPS and $117.57 million in revenue. The company has a positive Earnings ESP of +80.00% and a Zacks Rank #3, strong indicators that it will likely exceed consensus EPS estimates. Investors are advised to consider these metrics alongside other factors before the upcoming earnings release on February 19.
Ardelyx, Inc. $ARDX Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund significantly reduced its stake in Ardelyx, Inc. (NASDAQ:ARDX) by 69.5% in the third quarter, selling 172,800 shares and now holding 75,744 shares valued at approximately $417,000. Insider selling has also occurred, with Laura A. Williams selling 50,000 shares and insiders collectively selling 114,868 shares in the last ninety days. Despite these sales, Wall Street sentiment remains largely positive with an average "Buy" rating and a consensus target price of $14.36, suggesting notable upside potential for the stock which is currently trading around $7.26.
Ardelyx, Inc. (ARDX) Reports Strong 2025 Revenue Growth, Updates 2026 Outlook
Ardelyx, Inc. (ARDX) reported strong preliminary product revenue results for Q4 and full year 2025, with Ibsrela revenue increasing by 73% year over year. The company provided optimistic expected product revenue for 2026, an updated long-term outlook for Ibsrela, and announced the initiation of a Phase 3 program for Ibsrela in chronic idiopathic constipation, positioning itself for continued growth. Ardelyx projects Ibsrela to exceed $1 billion in peak sales with patent protection until 2041, and is also advancing a next-generation NHE3 inhibitor, RDX10531.
Ardelyx, Inc. to Host Conference Call for 2025 Financial Results and Business Update
Ardelyx, Inc. announced it will host a conference call on February 19, 2026, to discuss its financial results and business updates for the full year and fourth quarter of 2025. Key executives, including CEO Mike Raab and CFO Sue Hohenleitner, will participate. The company, which has two commercial products in the U.S. and a developing pipeline, will offer both call-in and webcast options for participation.
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Ardelyx, Inc. (Nasdaq: ARDX) announced it will report its full-year and fourth-quarter 2025 financial results on February 19, 2026. This will be followed by a conference call at 4:30 p.m. Eastern Time, featuring the Executive Leadership Team to discuss results and provide a business update. The company, focused on innovative medicines, currently has two commercial products, IBSRELA and XPHOZAH, and a pipeline including IBSRELA Phase 3 development and RDX10531.
Assessing Ardelyx (ARDX) Valuation After Patent Extension And Pipeline Progress
Ardelyx (ARDX) has secured a new US patent for its tenapanor formulations, IBSRELA and XPHOZAH, extending protection to 2042, and is advancing IBSRELA into a Phase 3 trial. Despite recent strong stock performance and a current valuation of US$7.74 against an analyst target of US$13.50, the company's valuation hinges on continued revenue growth, profitability inflection, and mitigating risks related to product concentration and reimbursement uncertainty for XPHOZAH.
Ardelyx receives new patent for Tenapanor
Ardelyx (ARDX) announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299, titled “Oral Formulations of Tenapanor,” with an expiration date of November 26, 2042. This patent covers the commercial formulations of their drugs Isbrela and Xphozah. The company plans to submit the patent to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations for both products.
Raymond James reiterates Strong Buy on Ardelyx stock after patent news By Investing.com
Raymond James has reaffirmed its "Strong Buy" rating and $19.00 price target for Ardelyx, Inc. (NASDAQ:ARDX) following the issuance of a new formulation patent for its drug tenapanor, which could extend its exclusivity to 2042. This patent development is seen to provide Ardelyx with enhanced negotiating leverage against potential generic competitors. The company also reported strong financial results for 2025, with total product revenue of approximately $378 million, and has initiated a Phase 3 clinical trial for IBSRELA.
Raymond James reiterates Strong Buy on Ardelyx stock after patent news
Raymond James has reiterated its "Strong Buy" rating and $19 price target for Ardelyx, Inc. (NASDAQ: ARDX) following the issuance of a new formulation patent for its drug tenapanor. This new patent for tenapanor (Patent No. 12,539,299) could extend the drug's market exclusivity until 2042, significantly beyond its current 2033/34 expiration, and analysts believe even a few additional years of exclusivity could add substantial value to Ardelyx's valuation. The company also reported strong financial results for 2025, with total product revenue up 18% year-over-year, largely driven by its lead product IBSRELA.
Raymond James reiterates Strong Buy on Ardelyx stock after patent news
Raymond James has reiterated its Strong Buy rating and $19.00 price target for Ardelyx, Inc. following a new formulation patent for its key drug, tenapanor. This patent could extend the drug's exclusivity until 2042, potentially adding significant value per share. Despite some investor skepticism, Ardelyx has shown strong financial results and revenue growth, with its lead product IBSRELA performing well.
Ardelyx (ARDX) Secures New Patent for Tenapanor Formulations
Ardelyx (ARDX) has been granted a new patent for its oral formulations of Tenapanor, extending protection until 2042. The patent covers the commercial formulations of their products Isbrela and Xphozah, which the company plans to submit to the FDA for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations. Despite strong revenue growth, Ardelyx faces profitability challenges and financial stress, as indicated by negative margins and a moderate debt level.
Ardelyx, Inc. Secures U.S. Patent for Tenapanor Formulations, Expiring November 2042
Ardelyx, Inc. announced the issuance of U.S. Patent No. 12,539,299 for its oral formulations of tenapanor, which includes the commercial formulations of IBSRELA and XPHOZAH. This patent extends protection for these products until November 26, 2042, and will be listed with the FDA in the Orange Book. Ardelyx CEO Mike Raab highlighted the patent's importance in safeguarding their innovative medicines, which address significant unmet medical needs in conditions like Irritable Bowel Syndrome and high phosphate levels in chronic kidney disease.
Ardelyx, Inc. Secures U.S. Patent for Tenapanor Formulations, Expiring November 2042
Ardelyx, Inc. announced the issuance of U.S. Patent No. 12,539,299 for its oral formulations of tenapanor, which covers its commercial products IBSRELA and XPHOZAH. The patent extends protection until November 26, 2042, enhancing the exclusivity period for these medicines. This development strengthens Ardelyx's intellectual property strategy and supports its mission to address significant unmet medical needs.
New patent shields Ardelyx gut drugs IBSRELA, XPHOZAH until 2042
Ardelyx announced that the USPTO has issued a new patent, U.S. Patent No. 12,539,299, covering the commercial formulations of its drugs IBSRELA and XPHOZAH. This patent protects the oral formulations of tenapanor until November 26, 2042. The company plans to submit this patent for listing in the FDA Orange Book, further strengthening its intellectual property.
Ardelyx, Inc. (ARDX) Gains TD Analysts Support Ahead of Q4 Results
TD Cowen and Jefferies have both raised their price targets for Ardelyx, Inc. (ARDX) and maintained Buy ratings, ahead of the company's Q4 results. Analysts highlight Ibsrela's sustained execution, potential upside from new indications, and projected peak sales of $1.5–$2 billion by 2035. Ardelyx is a biopharmaceutical company specializing in gastrointestinal and cardiorenal therapies.
Y Intercept Hong Kong Ltd Grows Stock Position in Ardelyx, Inc. $ARDX
Y Intercept Hong Kong Ltd significantly increased its stake in Ardelyx, Inc. (NASDAQ:ARDX) by 488% in the third quarter, now owning 306,547 shares valued at approximately $1.689 million. Despite this institutional growth, company insiders have been net sellers, disposing of 114,868 shares, while Wall Street analysts maintain a "Buy" consensus with an average target price of $14.36 for ARDX. The biopharmaceutical company recently reported strong quarterly earnings, beating analyst estimates for EPS and revenue.
Jefferies Remains a Buy on Ardelyx (ARDX)
Jefferies has reiterated a Buy rating on Ardelyx (ARDX) and increased its price target to $15, following BTIG's earlier price target increase to $17. The positive sentiment is driven by strong Ibsrela revenue growth, which was up 73% year-over-year in fiscal 2025 and is projected to grow 50-58% in fiscal 2026, with peak sales expected to exceed $1 billion by 2029. Citi also raised its price target for Ardelyx, noting management's optimistic revenue expectations.
Ardelyx begins phase 3 trial of IBSRELA for chronic constipation By Investing.com
Ardelyx, Inc. has initiated a Phase 3 clinical trial for IBSRELA (tenapanor) to treat chronic idiopathic constipation (CIC) in adults, marking a significant step to expand the drug's approved uses. The company's stock is trading near its 52-week high, following strong product revenue growth in 2025 and positive analyst ratings. This trial aims to enroll approximately 700 patients and is expected to provide topline data in the second half of 2027.
Ardelyx Draws Zydus Interest As IBSRELA Trial And Valuation Gain Focus
Ardelyx is catching investor attention due to reported interest from Zydus Lifesciences in acquiring a majority stake and the initiation of a Phase 3 clinical trial for its drug IBSRELA for chronic idiopathic constipation. The stock has shown strong recent performance, with returns of 37.5% over the past 30 days and 169.3% over three years, while still trading significantly below analyst targets and an estimated fair value. Investors are advised to monitor progress on the potential acquisition talks and the clinical trial, as these events could lead to further sharp movements in the share price.
Ardelyx Draws Zydus Interest As IBSRELA Trial And Valuation Gain Focus
Ardelyx is gaining investor interest due to Zydus Lifesciences exploring a majority stake acquisition and the initiation of a Phase 3 clinical trial for IBSRELA in chronic idiopathic constipation. The company's stock, currently at $7.89, has seen significant returns over various periods and is considered undervalued by Simply Wall St's analysis compared to analyst targets. These developments highlight a critical period for Ardelyx, with potential impacts on its future business and risk profile.
New 700-patient constipation drug trial begins, targeting 34M adults
Ardelyx announced the initiation of ACCEL, a Phase 3 clinical trial for its drug IBSRELA (tenapanor) to treat chronic idiopathic constipation (CIC) in adults. This randomized, double-blind, placebo-controlled study plans to enroll approximately 700 patients, with topline data anticipated in the second half of 2027. The trial aims to expand IBSRELA's market beyond irritable bowel syndrome with constipation (IBS-C) to the broader CIC population, estimated to affect over 34 million Americans.
Is It Too Late To Consider Ardelyx (ARDX) After The Recent Share Price Surge?
Ardelyx (ARDX) shares have seen significant recent gains, with the stock currently trading around US$7.80. Despite this surge, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 88.7%, with an estimated intrinsic value of US$69.10 per share. The company also appears undervalued based on its Price/Sales ratio of 4.76x compared to industry and "Fair Ratio" averages.
All You Need to Know About Ardelyx (ARDX) Rating Upgrade to Buy
Ardelyx (ARDX) has received an upgrade to a Zacks Rank #2 (Buy), driven by a significant upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which could lead to increased buying pressure and a rise in its stock price. The Zacks system, recognized for its strong correlation between earnings estimate revisions and stock movements, indicates Ardelyx's improved underlying business and potential for market-beating returns.
Palisades Investment Partners LLC Cuts Position in Ardelyx, Inc. $ARDX
Palisades Investment Partners LLC significantly reduced its stake in Ardelyx, Inc. (NASDAQ:ARDX) by 98.1% in Q3, selling 511,093 shares and retaining only 10,147 shares valued at $56,000. Despite this, analysts largely maintain a "Buy" rating with an average target price of $14.30. Company insiders have also been net sellers, disposing of over $700,000 worth of shares in the last 90 days.
Ardelyx (ARDX) price target increased by 12.82% to 13.46
The article reports that the price target for Ardelyx (ARDX) has been increased by 12.82%, reaching a new target of 13.46. This increase suggests a positive outlook from analysts or market sentiment regarding the company's future performance.
Wedbush Increases Ardelyx (NASDAQ:ARDX) Price Target to $19.00
Wedbush has increased its price target for Ardelyx (NASDAQ:ARDX) to $19.00 from $16.00, maintaining an "outperform" rating and implying a significant upside. The biopharmaceutical company holds a consensus "Buy" rating from analysts with an average target price of $14.30. Ardelyx recently exceeded quarterly revenue and EPS estimates, reporting $110.33 million in revenue and $0.00 EPS.
Ardelyx stock hits 52-week high at 8.06 USD
Ardelyx Inc. (ARDX) stock has reached a 52-week high of $8.06 USD, marking a significant increase of 58.04% over the past year and 75.57% in the last six months. The biopharmaceutical company, valued at $1.94 billion, has a "Strong Buy" consensus from analysts with a high price target of $19. Recent financial results for 2025 show total product revenue of $378 million, an 18% year-over-year growth, largely driven by its lead product Ibsrela.
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Ardelyx (NASDAQ: ARDX) shares recently gained 37% in the last month, contributing to a 58% annual gain. Despite this surge, its price-to-sales (P/S) ratio of 4.7x suggests it may still be undervalued compared to the broader Biotech industry, where many companies have P/S ratios exceeding 11.4x. However, analysts predict Ardelyx's revenue growth of 28% per year over the next three years will significantly lag the industry's projected 126% growth, contributing to its lower P/S ratio.
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Ardelyx, Inc. (NASDAQ:ARDX) has seen its shares jump 37% in the last month, contributing to a 58% annual gain. Despite this recent surge, its price-to-sales (P/S) ratio of 4.7x remains significantly lower than the biotech industry average, suggesting it may still be a strong buying opportunity. However, analysts predict Ardelyx's revenue growth of 28% per year over the next three years will lag the industry's projected 126% growth, contributing to its current low valuation.
Zydus Gets World’s First Menkes Disease Drug Approval Amid Ardelyx Acquisition Speculation
Zydus has received the world's first drug approval for Menkes disease, a significant development for the company. This approval comes amidst ongoing speculation regarding Zydus's potential acquisition of Ardelyx. The article highlights Zydus's increasing investment successes and recent approvals for other drugs.
Zydus Lifesciences eyes $2.5 billion US biopharma buyout of Ardelyx: Report
Zydus Lifesciences is reportedly considering acquiring a majority stake in US-based biopharmaceutical company Ardelyx Inc. for an estimated $2.2–2.5 billion. This potential acquisition aligns with Zydus's strategy to expand into global innovative medicine, moving beyond its generics business. The deal would be funded through a Rs 5,000-crore equity raise via QIP and internal cash reserves.
Ardelyx Shares Soar as Analysts Raise Price Targets
Ardelyx Inc. (NASDAQ: ARDX) stock has surged by 14.3% following promising FDA feedback and increased investor optimism, with analysts raising price targets due to strong revenue projections for its drugs IBSRELA and XPHOZAH. Firms like Raymond James, Piper Sandler, BTIG, and Citi have issued bullish ratings and raised targets, anticipating Ardelyx will achieve $1 billion in IBSRELA revenues by 2029. The company's financial strength and strategic market expansion outline a positive trajectory in the pharmaceutical sector.
Ardelyx Stock Surges Amid Upgraded Ratings and Revenue Projections
Ardelyx Inc. (NASDAQ: ARDX) stock surged by 9.93% following positive sentiment driven by upgraded ratings from Raymond James and Piper Sandler, and strong revenue projections for its IBSRELA and XPHOZAH products. The company anticipates preliminary revenues of $378M for FY25 and up to $430M for IBSRELA in 2026, with market analysts projecting IBSRELA sales could exceed $1B by 2029. These positive indicators, along with extended intellectual property rights until 2041, suggest a strong growth trajectory for Ardelyx.
Zydus Lifesciences eyes acquisition of US firm Ardelyx for $2.5 billion | Company Business News
Zydus Lifesciences is reportedly evaluating the acquisition of a majority stake in US-based Ardelyx Inc. for an estimated $2.2–2.5 billion. This strategic move aims to significantly boost Zydus's presence in global innovative medicine, diversifying its portfolio beyond generic drugs. The deal is expected to be financed through a ₹5,000-crore equity raise via a qualified institutional placement and internal cash reserves.
Zydus Life may acquire US-firm Ardelyx; may fund deal via QIP
Zydus Lifesciences is reportedly planning to acquire US biopharma firm Ardelyx, either by obtaining a majority stake or purchasing key molecules. To finance this acquisition, Zydus plans to raise funds through a qualified institutional placement (QIP), which was previously approved to deleverage its balance sheet and pursue opportunities in the US specialty business. Ardelyx has a market capitalization of $1.6 billion and two commercial products approved in the US: IBSRELA and XYPHOZAH.
